Stock Events

Stock Events

Outlook Therapeutics

0

189

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Outlook Therapeutics

Earnings

14AugExpected

Q1 2026

Q2 2026

-0.14

-0.11

-0.09

-0.07

Expected EPS

-0.0691408

Actual EPS

-0.12099640000000002

Financials

-4,542.75%Profit Margin

Unprofitable

2020

2021

2022

2023

2024

2025

1.2MRevenue

-54.48MNet Income

Analyst Ratings

3.95Average Price Target

The highest estimate is 7.59.
From 3 ratings within the last 6 months. This is not an investment recommendation.

Buy

67%

Hold

33%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 41ON.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals competes in the ophthalmology space, particularly with treatments for eye diseases, directly competing with Outlook Therapeutics' eye therapy products.

REGENXBIO Inc. focuses on the development of gene therapy products for eye diseases, offering direct competition to Outlook Therapeutics' gene therapy approaches for ocular diseases.

Novartis AG has a strong presence in the ophthalmology market, including therapies for macular degeneration and other eye conditions, competing with Outlook Therapeutics.

Bausch Health Companies

Bausch Health Companies Inc., through its eye health division, provides a wide range of products for eye conditions, directly competing with Outlook Therapeutics.

AbbVie, after acquiring Allergan, has become a significant player in the eye care market, offering products that compete with Outlook Therapeutics' treatments.

Roche Holding AG, with its ophthalmology division, offers treatments for various eye diseases, competing with Outlook Therapeutics in the broader eye care market.

Pfizer Inc. has investments in treatments for eye diseases, including therapies for retinal disorders, making it a competitor to Outlook Therapeutics.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical division, develops treatments for eye health, including surgery and vision care, competing with Outlook Therapeutics.

GlaxoSmithKline plc, with its healthcare portfolio, includes treatments for eye conditions, indirectly competing with Outlook Therapeutics in the healthcare market.

About

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Show more...

CEO

Robert Charles Jahr

Employees

17

Country

United States

ISIN

US69012T2069

Listings

0 Comments

Share your thoughts

FAQ

What is Outlook Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Outlook Therapeutics stocks are traded under the ticker 41ON.MU.

When is the next Outlook Therapeutics earnings date?▼

Outlook Therapeutics is going to release the next earnings report on December 18, 2026.

What were Outlook Therapeutics earnings last quarter?▼

41ON.MU earnings for the last quarter are -0.12 EUR per share, whereas the estimation was -0.07 EUR resulting in a -75% surprise. The estimated earnings for the next quarter are N/A EUR per share.

What is Outlook Therapeutics revenue for the last year?▼

Outlook Therapeutics revenue for the last year amounts to 1.2M EUR.

What is Outlook Therapeutics net income for the last year?▼

41ON.MU net income for the last year is -54.48M EUR.

How many employees does Outlook Therapeutics have?▼

As of September 04, 2026, the company has 17 employees.

In which sector is Outlook Therapeutics located?▼

Outlook Therapeutics operates in the Health & Wellness sector.

When did Outlook Therapeutics complete a stock split?▼

The last stock split for Outlook Therapeutics was on March 14, 2024 with a ratio of 1:20.

Where is Outlook Therapeutics headquartered?▼

Outlook Therapeutics is headquartered in ISELIN, United States.